Baird has downgraded Carisma Therapeutics (NASDAQ:CARM) to neutral from outperform, citing a lack of near-term catalysts. The ...

D. Boral Capital analyst Jason Kolbert says investors should “stay the course” on Carisma Therapeutics (CARM) amid the rating downgrades ...

Carisma Therapeutics (CARM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

The newly announced restructure includes several company leaders hitting the exit and the discontinuation of the biotech’s ...

Fintel reports that on December 12, 2024, Baird downgraded their outlook for Carisma Therapeutics (NasdaqGM:CARM) from ...

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price target decreased by D. Boral Capital from $24.00 to $12.00 in a report released on Monday,Benzinga reports. The firm presently has a ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of ...

PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused ...

PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused ...

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages ...